In 721 children and young adults with newly diagnosed FLT3 wild-type AML, CPX-351 induction was inferior to standard daunorubicin/cytarabine at interim analysis (2-year EFS 51.2% vs 62.2%), stopping randomisation; the gap was driven mainly by low-risk patients.
RCTn = 721
Pollard et al. AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group